Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- The diversity of RNA species
- The diversity of mRNA
- Our focus is mRNA: how does it work?
- mRNA vaccines against SARS CoV-2
- Differences between RNA vaccines
- mRNA vs. viral vector vaccines
- Why mRNA? Why now?
- Obstacles overcome
- The limitless potential of RNA Therapeutics
- mRNA therapeutic companies
- Moderna pipeline and partners
- VEGF mRNA for ischemia (1)
- VEGF mRNA for ischemia (2)
- VEGF mRNA for ischemia (3)
- mRNA for cystic fibrosis
- What next? Roadmap for RNA therapeutics
- Hospital-based RNA therapeutics
- Democratizing RNA therapeutics
- RNA therapeutics and cancer
- RNA stability and translation
- Innovation in RNA therapeutics: STAMP
- Innovation in RNA therapeutics: circular RNA
- Innovations in delivery: nanotherapeutics
- Leukosomes target inflamed tissues
- Melanoma vaccine
- Personalized cancer vaccines
- Chagas disease vaccine
- aYAP mRNA for cardiac regeneration
- Inducing pacemaker cells using mRNAa
- LDL metabolism and mRNA therapeutic targets
- mRNA regenerative therapy
- mRNA therapy for progeria (HGPS)
- Pathobiology of progeria
- hTERT mRNA for progeria
- Reversal of senescence by mRNA hTERT
- Beneficial effects of mTERT in HGPS mice
- hTERT-enhanced skin product
- Conclusion
- RNA therapeutics at HMH
Topics Covered
- The diversity of RNA species
- The diversity of mRNA
- mRNA vaccines
- mRNA vs. viral vector vaccines
- Obstacles overcome
- The limitless potential of RNA therapeutics
- VEGF mRNA for ischemia
- mRNA for cystic fibrosis
- Roadmap for RNA therapeutics
- RNA therapeutics and cancer
- Innovation in RNA therapeutics
- aYAP mRNA for cardiac regeneration
- mRNA therapy for progeria (HGPS)
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Cooke, J.P. (2022, November 30). RNA therapeutics: clinical applications and methods of delivery [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 6, 2024, from https://doi.org/10.69645/CKKT7197.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Cooke is the Founding Director of the Center for RNA Therapeutics at Houston Methodist Hospital, and is an inventor on trade secrets related to the manufacturing of RNA drugs. In addition, Dr. Cooke is an inventor on patents assigned to Stanford University or Houston Methodist Hospital on the use of mRNA telomerase for cellular rejuvenation.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Professor John Cooke.
I'm the founding Director of the
Center for RNA Therapeutics here
at Houston Methodist
Research Institute
in the Texas Medical Center.
Today's Henry Stewart
Talk is going to
be about "RNA Therapeutics, Clinical
Applications, and Methods of Delivery".
0:22
Before I begin, let me
disclose my conflicts.
I am an inventor on RNA
technologies assigned
to Stanford University and to
Houston Methodist Hospital.
I'm the founder of
ChromeX Bio which is
developing mRNA
telomerase therapies.
I'm a member of the Scientific Advisory
Board of Humann, Cordex Bio,and JanOne.
And I'm the principal
investigator on
sponsored research agreements
with Avita and VGXI.
0:50
We're going to be talking
today about messenger RNA,
but just a slide to remind us
of the diversity of RNA species.
In addition to messenger
RNA, there's transfer RNA,
ribosomal RNA, microRNA, long
non-coding RNA, et cetera.
That diversity of
RNA also represents
some great opportunities for
therapeutic development.
1:13
Indeed, there is a diversity of
RNA drugs becoming available
and becoming
clinically approved.
Most of the approved
drugs at the moment are
antisense oligonucleotides and
interference RNA products.
But messenger RNA, of course,
is also coming down the pike.
1:32
We know that messenger
RNA works because it
is essentially
biological software,
the cellular instructions
to make any protein.
The idea for
therapeutic RNA is that
one gets it into the
cell of interest
and that messenger RNA
in the cytoplasm gets
translated into therapeutic
proteins by the ribosomes.